GTC Biotherapeutics, Inc. (GTCB.O)
0.74USD
17 Dec 2009
$-0.05 (-5.85%)
$0.79
$0.76
$0.77
$0.72
15,826
30,148
$9.50
$0.65
GTCB.O
About
Overall
| Beta: | 0.40 |
| Market Cap (Mil.): | $8.24 |
| Shares Outstanding (Mil.): | 10.49 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| GTCB.O | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 12.05 | 4.64 |
| EPS (TTM): | 9.15 | -- | -- |
| ROI: | -303.20 | 1.33 | 2.79 |
| ROE: | -- | 2.17 | 3.51 |
Lundbeck launches drug from DNA-altered goats
* Danish company launches anti-clotting drug ATryn in U.S.
U.S. approves first drug from DNA-altered animals
WASHINGTON (Reuters) - U.S. health officials on Friday approved the first drug made using genetically engineered animals despite lingering concerns over health and environmental implications.
UPDATE 3-U.S. approves first drug from DNA-altered animals
WASHINGTON, Feb 6 (Reuters) - U.S. health officials on Friday approved the first drug made using genetically engineered animals despite lingering concerns over health and environmental implications.
U.S. approves first drug from DNA-altered animals
WASHINGTON (Reuters) - U.S. health officials on Friday approved the first drug made using genetically engineered animals, amid lingering concerns about genetic implications.
US FDA approves GTC's animal-based drug Atryn
WASHINGTON, Feb 6 (Reuters) - The U.S. Food and Drug Administration has approved GTC Biotherapeutics Inc's experimental anticlotting therapy called Atryn, a spokesman for the company said on Friday.
U.S. advisers back 1st drug from DNA-altered animals
ROCKVILLE, Maryland (Reuters) - The first drug made using genetically engineered animals to near U.S. approval won key support on Friday from an advisory panel that judged it safe and effective despite concerns from groups worried about the genetic tinkering.
U.S. advisers back 1st drug from DNA-altered animals
ROCKVILLE, Maryland (Reuters) - The first drug made using genetically engineered animals to near U.S. approval won key support on Friday from an advisory panel that judged it safe and effective despite concerns from groups worried about the genetic tinkering.
UPDATE 2-US advisers back 1st drug from DNA-altered animals
(Recasts first paragraph, adds FDA and company comments, detail on the drug)
U.S. panel backs first drug from DNA-altered animals
ROCKVILLE, Maryland (Reuters) - A U.S. advisory panel recommended approval of what would be the first drug made using genetically engineered animals on the U.S. market, saying it appeared safe and effective despite concerns heard from groups worried about the genetic tinkering.
UPDATE 1-US panel backs first drug from DNA-altered animals
ROCKVILLE, Md., Jan 9 (Reuters) - A U.S. advisory panel recommended approval of what would be the first drug made using genetically engineered animals on the U.S. market, saying it appeared safe and effective despite concerns heard from groups worried about the genetic tinkering.
Competitors
| Price | Change | |
|---|---|---|
| Talecris Biotherapeutics Holdings Corp (TLCR.OQ) | $21.60 | -0.09 |
| Grifols SA (GRLS.MC) | €11.68 | -0.02 |
| Baxter International Inc. (BAX.N) | $57.98 | -0.45 |
| Pfizer Inc. (PFE.N) | $18.22 | -0.19 |
| CSL Limited (CSL.AX) | $31.04 | +0.40 |
| Novo Nordisk A/S (NOVOb.CO) | kr.335.50 | +3.50 |
| Wyeth (WYE.N) | -- | -- |
| Wyeth (WYE_p.N) | -- | -- |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
